Cogent Biosciences, Inc. (COGT) 10-Year Financial Performance & Capital Metrics

COGT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA -$272M -32.8%
Net Income -$256M -33.0%
EPS (Diluted) -2.46 -1.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -99.54% -32.8%
ROIC -103.73% -19.3%
Debt/Equity 0.07 -6.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 30.4% in last year
✗Expensive at 15.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.49%

EPS CAGR

10Y-

5Y-

3Y-

TTM0%

ROCE

10Y Avg-55.17%

5Y Avg-66.09%

3Y Avg-79.02%

Latest-100.81%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.99M	6.36M	8.36M	9.73M	22.5M	7.87M	0	0	0	0
Revenue Growth %	-	1.13%	0.32%	0.16%	1.31%	-0.65%	-1%	-	-	-
Cost of Goods Sold+	0	0	0	0	43.71K	25.74M	0	0	0	0
COGS % of Revenue	-	-	-	-	0%	3.27%	-	-	-	-
Gross Profit+	2.99M	6.36M	8.36M	9.73M	22.46M	-17.87M	0	0	0	0
Gross Margin %	1%	1%	1%	1%	1%	-2.27%	-	-	-	-
Gross Profit Growth %	-	1.13%	0.32%	0.16%	1.31%	-1.8%	1%	-	-	-
Operating Expenses+	9.58M	25.43M	34.51M	45.74M	54.68M	64.33M	75.55M	147.84M	208.13M	275.94M
OpEx % of Revenue	3.21%	4%	4.13%	4.7%	2.43%	8.17%	-	-	-	-
Selling, General & Admin	2.73M	3.43M	4.68M	7.45M	10.97M	17.42M	19.64M	26.21M	34.38M	43.28M
SG&A % of Revenue	0.91%	0.54%	0.56%	0.77%	0.49%	2.21%	-	-	-	-
Research & Development	6.85M	21.99M	29.83M	38.28M	43.71M	72.65M	55.91M	121.63M	173.75M	232.66M
R&D % of Revenue	2.29%	3.46%	3.57%	3.93%	1.94%	9.23%	-	-	-	-
Other Operating Expenses	0	0	274K	320K	78K	-25.74M	0	0	0	0
Operating Income+	-6.59M	-19.07M	-26.15M	-36.01M	-32.18M	-82.2M	-75.55M	-147.84M	-208.13M	-275.94M
Operating Margin %	-2.21%	-3%	-3.13%	-3.7%	-1.43%	-10.44%	-	-	-	-
Operating Income Growth %	-	-1.89%	-0.37%	-0.38%	0.11%	-1.55%	0.08%	-0.96%	-0.41%	-0.33%
EBITDA+	-6.41M	-18.24M	-24.98M	-34.68M	-30.89M	-81.48M	-73.56M	-141.96M	-204.54M	-271.59M
EBITDA Margin %	-2.15%	-2.87%	-2.99%	-3.56%	-1.37%	-10.35%	-	-	-	-
EBITDA Growth %	-	-1.84%	-0.37%	-0.39%	0.11%	-1.64%	0.1%	-0.93%	-0.44%	-0.33%
D&A (Non-Cash Add-back)	179K	830K	1.17M	1.32M	1.29M	720K	1.99M	5.88M	3.59M	4.35M
EBIT	-6.59M	-19.07M	-26.15M	-36.01M	-32.18M	-35.29M	-75.55M	-147.84M	-208.13M	-275.94M
Net Interest Income+	0	265K	386K	1.15M	267K	144K	467K	0	13.08M	18.09M
Interest Income	0	265K	386K	1.15M	267K	144K	467K	3.99M	13.08M	18.09M
Interest Expense	0	0	0	0	0	0	0	3.99M	0	0
Other Income/Expense	0	946K	660K	1.47M	345K	7.39M	3.28M	7.6M	15.72M	20.08M
Pretax Income+	-6.59M	-18.12M	-25.49M	-34.53M	-31.83M	-74.81M	-72.27M	-140.24M	-192.41M	-255.86M
Pretax Margin %	-2.21%	-2.85%	-3.05%	-3.55%	-1.41%	-9.5%	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.95%	1%	1%	1%	1%	1%
Net Income+	-6.59M	-18.12M	-25.49M	-34.53M	-30.27M	-74.81M	-72.27M	-140.24M	-192.41M	-255.86M
Net Margin %	-2.21%	-2.85%	-3.05%	-3.55%	-1.35%	-9.5%	-	-	-	-
Net Income Growth %	-	-1.75%	-0.41%	-0.35%	0.12%	-1.47%	0.03%	-0.94%	-0.37%	-0.33%
Net Income (Continuing)	-6.59M	-18.12M	-25.49M	-34.53M	-31.83M	-74.81M	-72.27M	-140.24M	-192.41M	-255.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.89	-2.45	-3.45	-5.55	-3.97	-6.00	-1.85	-2.26	-2.42	-2.46
EPS Growth %	-	-1.75%	-0.41%	-0.61%	0.28%	-0.51%	0.69%	-0.22%	-0.07%	-0.02%
EPS (Basic)	-1.13	-3.10	-3.45	-5.55	-3.97	-6.00	-1.85	-2.26	-2.42	-2.46
Diluted Shares Outstanding	7.4M	7.4M	7.4M	6.22M	7.62M	11.08M	38.73M	58.74M	79.66M	103.86M
Basic Shares Outstanding	5.86M	5.86M	7.4M	6.22M	7.62M	11.08M	38.73M	58.74M	79.66M	103.86M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	91.1M	69.73M	42.38M	81M	40.59M	244.91M	222.63M	264.97M	270.77M	296.47M
Cash & Short-Term Investments	90.48M	68.51M	40.96M	78.59M	37.42M	242.19M	219.68M	259.28M	265.71M	287.08M
Cash Only	90.48M	41.32M	28.27M	55.67M	37.42M	242.19M	219.68M	139.89M	53.23M	98.17M
Short-Term Investments	0	27.19M	12.69M	22.92M	0	0	0	119.39M	212.48M	188.91M
Accounts Receivable	294K	928K	830K	1.67M	2M	0	0	0	0	0
Days Sales Outstanding	35.94	53.3	36.24	62.55	32.45	-	-	-	-	-
Inventory	0	0	75K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	326K	0	75K	740K	0	0	0	1.25M	5.06M	9.39M
Total Non-Current Assets+	3.67M	5.82M	6.74M	4.92M	8.83M	6M	9.46M	35.84M	42.67M	31.43M
Property, Plant & Equipment	2.42M	4.56M	4.11M	3.25M	7.15M	4.75M	4.48M	31.1M	30.34M	26.56M
Fixed Asset Turnover	1.24x	1.39x	2.04x	2.99x	3.15x	1.66x	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	1.25M	1.25M	1.25M	1.25M	0	0	0	0	7.46M	0
Other Non-Current Assets	0	0	1.37M	419K	1.68M	1.25M	4.98M	4.75M	4.86M	4.86M
Total Assets+	94.77M	75.55M	49.12M	85.93M	49.42M	250.92M	232.09M	300.81M	313.44M	327.9M
Asset Turnover	0.03x	0.08x	0.17x	0.11x	0.46x	0.03x	-	-	-	-
Asset Growth %	-	-0.2%	-0.35%	0.75%	-0.42%	4.08%	-0.08%	0.3%	0.04%	0.05%
Total Current Liabilities+	7.29M	8.74M	11.19M	24.95M	13.25M	13.09M	17.08M	26.85M	38.17M	55.71M
Accounts Payable	1.4M	1.45M	1.35M	1.52M	3.18M	732K	3.48M	5.84M	10.65M	12.01M
Days Payables Outstanding	-	-	-	-	26.58K	10.38	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	0	1000K	1000K	0	0
Other Current Liabilities	606K	118K	1.64M	3.88M	3.39M	7.28M	3.62M	6.47M	10.31M	12.63M
Current Ratio	12.49x	7.98x	3.79x	3.25x	3.06x	18.70x	13.04x	9.87x	7.09x	5.32x
Quick Ratio	12.49x	7.98x	3.78x	3.25x	3.06x	18.70x	13.04x	9.87x	7.09x	5.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17.96M	14.43M	9.62M	748K	4.41M	3.15M	831K	18.23M	17.47M	15.9M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	4.41M	3.15M	831K	18.23M	17.47M	15.9M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	665K	908K	906K	748K	0	0	0	0	0	0
Total Liabilities	25.25M	23.16M	20.81M	25.69M	17.66M	16.25M	17.91M	45.08M	55.63M	71.61M
Total Debt+	0	0	0	0	6.03M	5.21M	3.15M	19.65M	18.85M	17.47M
Net Debt	-90.48M	-41.32M	-28.27M	-55.67M	-31.39M	-236.98M	-216.53M	-120.24M	-34.38M	-80.7M
Debt / Equity	-	-	-	-	0.19x	0.02x	0.01x	0.08x	0.07x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-37.06x	-	-
Total Equity+	69.52M	52.39M	28.3M	60.23M	31.76M	234.67M	214.18M	255.74M	257.8M	256.29M
Equity Growth %	-	-0.25%	-0.46%	1.13%	-0.47%	6.39%	-0.09%	0.19%	0.01%	-0.01%
Book Value per Share	9.40	7.08	3.83	9.68	4.17	21.18	5.53	4.35	3.24	2.47
Total Shareholders' Equity	69.52M	52.39M	28.3M	60.23M	31.76M	234.67M	214.18M	255.74M	257.8M	256.29M
Common Stock	16K	10K	10K	30K	8K	32K	44K	70K	86K	110K
Retained Earnings	-7.72M	-25.85M	-51.34M	-92.06M	-123.89M	-198.7M	-270.97M	-411.21M	-603.62M	-859.48M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-16K	-24K	-16K	-12K	0	0	0	-104K	246K	447K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	17.72M	-18.64M	-25.84M	-32.49M	-41.51M	-35.85M	-58.76M	-118.64M	-153.62M	-207.79M
Operating CF Margin %	5.93%	-2.93%	-3.09%	-3.34%	-1.85%	-4.55%	-	-	-	-
Operating CF Growth %	-	-2.05%	-0.39%	-0.26%	-0.28%	0.14%	-0.64%	-1.02%	-0.29%	-0.35%
Net Income	-6.59M	-18.12M	-25.49M	-34.53M	-31.83M	-74.81M	-72.27M	-140.24M	-192.41M	-255.86M
Depreciation & Amortization	179K	830K	1.17M	1.32M	1.29M	720K	147K	5.88M	3.59M	4.35M
Stock-Based Compensation	248K	1.02M	1.34M	3.09M	0	6.02M	11.69M	18.37M	30.62M	39.74M
Deferred Taxes	-248K	17K	17K	-236K	0	0	0	0	0	0
Other Non-Cash Items	248K	-56K	7K	23K	3.11M	37.54M	-343K	-3.39M	-6.87M	-7.62M
Working Capital Changes	23.88M	-2.32M	-2.88M	-2.15M	-14.08M	-5.32M	2.02M	751K	11.44M	11.6M
Change in Receivables	-294K	-634K	98K	-838K	-332K	2M	0	0	0	0
Change in Inventory	220K	784K	931K	2.21M	0	0	0	0	0	0
Change in Payables	705K	389K	-31K	367K	1.66M	-2.45M	2.75M	2.36M	4.81M	1.36M
Cash from Investing+	-3.25M	-30.43M	13.51M	-10.53M	23.16M	8.42M	-1.72M	-124.72M	-97.82M	38.28M
Capital Expenditures	-1.99M	-3.31M	-912K	-549K	-33K	0	-1.72M	-6.86M	-2.8M	-573K
CapEx % of Revenue	0.67%	0.52%	0.11%	0.06%	0%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.25M	50K	-75K	0	0	8.42M	0	-117.86K	0	0
Cash from Financing+	70.75M	-40K	-729K	70.35M	108K	232.2M	37.98M	163.56M	163.54M	214.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-40K	-789K	-1.45M	0	560K	-30K	1.61M	0	1.11M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	15.72M	-21.95M	-26.75M	-33.04M	-41.55M	-35.85M	-60.48M	-125.5M	-156.42M	-208.36M
FCF Margin %	5.27%	-3.45%	-3.2%	-3.39%	-1.85%	-4.55%	-	-	-	-
FCF Growth %	-	-2.4%	-0.22%	-0.24%	-0.26%	0.14%	-0.69%	-1.08%	-0.25%	-0.33%
FCF per Share	2.13	-2.97	-3.62	-5.31	-5.45	-3.24	-1.56	-2.14	-1.96	-2.01
FCF Conversion (FCF/Net Income)	-2.69x	1.03x	1.01x	0.94x	1.37x	0.48x	0.81x	0.85x	0.80x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-9.48%	-29.73%	-63.18%	-78%	-65.81%	-56.16%	-32.2%	-59.69%	-74.94%	-99.54%
Return on Invested Capital (ROIC)	-	-	-353.34%	-1174.59%	-978.45%	-	-	-166.54%	-86.98%	-103.73%
Gross Margin	100%	100%	100%	100%	99.81%	-227%	-	-	-	-
Net Margin	-220.76%	-285.19%	-304.93%	-354.76%	-134.55%	-950.43%	-	-	-	-
Debt / Equity	-	-	-	-	0.19x	0.02x	0.01x	0.08x	0.07x	0.07x
Interest Coverage	-	-	-	-	-	-	-	-37.06x	-	-
FCF Conversion	-2.69x	1.03x	1.01x	0.94x	1.37x	0.48x	0.81x	0.85x	0.80x	0.81x
Revenue Growth	-	112.83%	31.55%	16.44%	131.14%	-65.02%	-100%	-	-	-

Revenue by Segment

	2018	2019
Preclinical Research And Clinical Development	25M	25M
Preclinical Research And Clinical Development Growth	-	0.00%

Frequently Asked Questions

Growth & Financials

Cogent Biosciences, Inc. (COGT) grew revenue by 0.0% over the past year. Growth has been modest.

Cogent Biosciences, Inc. (COGT) reported a net loss of $294.4M for fiscal year 2024.

Dividend & Returns

Cogent Biosciences, Inc. (COGT) has a return on equity (ROE) of -99.5%. Negative ROE indicates the company is unprofitable.

Cogent Biosciences, Inc. (COGT) had negative free cash flow of $246.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cogent Biosciences, Inc. (COGT) 10-Year Financial Performance & Capital Metrics

COGT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $0
EBITDA -$272M -32.8%
Net Income -$256M -33.0%
EPS (Diluted) -2.46 -1.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -99.54% -32.8%
ROIC -103.73% -19.3%
Debt/Equity 0.07 -6.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 97 (top 3%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 30.4% in last year
✗Expensive at 15.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-21.49%

EPS CAGR

10Y-

5Y-

3Y-

TTM0%

ROCE

10Y Avg-55.17%

5Y Avg-66.09%

3Y Avg-79.02%

Latest-100.81%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.99M	6.36M	8.36M	9.73M	22.5M	7.87M	0	0	0	0
Revenue Growth %	-	1.13%	0.32%	0.16%	1.31%	-0.65%	-1%	-	-	-
Cost of Goods Sold+	0	0	0	0	43.71K	25.74M	0	0	0	0
COGS % of Revenue	-	-	-	-	0%	3.27%	-	-	-	-
Gross Profit+	2.99M	6.36M	8.36M	9.73M	22.46M	-17.87M	0	0	0	0
Gross Margin %	1%	1%	1%	1%	1%	-2.27%	-	-	-	-
Gross Profit Growth %	-	1.13%	0.32%	0.16%	1.31%	-1.8%	1%	-	-	-
Operating Expenses+	9.58M	25.43M	34.51M	45.74M	54.68M	64.33M	75.55M	147.84M	208.13M	275.94M
OpEx % of Revenue	3.21%	4%	4.13%	4.7%	2.43%	8.17%	-	-	-	-
Selling, General & Admin	2.73M	3.43M	4.68M	7.45M	10.97M	17.42M	19.64M	26.21M	34.38M	43.28M
SG&A % of Revenue	0.91%	0.54%	0.56%	0.77%	0.49%	2.21%	-	-	-	-
Research & Development	6.85M	21.99M	29.83M	38.28M	43.71M	72.65M	55.91M	121.63M	173.75M	232.66M
R&D % of Revenue	2.29%	3.46%	3.57%	3.93%	1.94%	9.23%	-	-	-	-
Other Operating Expenses	0	0	274K	320K	78K	-25.74M	0	0	0	0
Operating Income+	-6.59M	-19.07M	-26.15M	-36.01M	-32.18M	-82.2M	-75.55M	-147.84M	-208.13M	-275.94M
Operating Margin %	-2.21%	-3%	-3.13%	-3.7%	-1.43%	-10.44%	-	-	-	-
Operating Income Growth %	-	-1.89%	-0.37%	-0.38%	0.11%	-1.55%	0.08%	-0.96%	-0.41%	-0.33%
EBITDA+	-6.41M	-18.24M	-24.98M	-34.68M	-30.89M	-81.48M	-73.56M	-141.96M	-204.54M	-271.59M
EBITDA Margin %	-2.15%	-2.87%	-2.99%	-3.56%	-1.37%	-10.35%	-	-	-	-
EBITDA Growth %	-	-1.84%	-0.37%	-0.39%	0.11%	-1.64%	0.1%	-0.93%	-0.44%	-0.33%
D&A (Non-Cash Add-back)	179K	830K	1.17M	1.32M	1.29M	720K	1.99M	5.88M	3.59M	4.35M
EBIT	-6.59M	-19.07M	-26.15M	-36.01M	-32.18M	-35.29M	-75.55M	-147.84M	-208.13M	-275.94M
Net Interest Income+	0	265K	386K	1.15M	267K	144K	467K	0	13.08M	18.09M
Interest Income	0	265K	386K	1.15M	267K	144K	467K	3.99M	13.08M	18.09M
Interest Expense	0	0	0	0	0	0	0	3.99M	0	0
Other Income/Expense	0	946K	660K	1.47M	345K	7.39M	3.28M	7.6M	15.72M	20.08M
Pretax Income+	-6.59M	-18.12M	-25.49M	-34.53M	-31.83M	-74.81M	-72.27M	-140.24M	-192.41M	-255.86M
Pretax Margin %	-2.21%	-2.85%	-3.05%	-3.55%	-1.41%	-9.5%	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.95%	1%	1%	1%	1%	1%
Net Income+	-6.59M	-18.12M	-25.49M	-34.53M	-30.27M	-74.81M	-72.27M	-140.24M	-192.41M	-255.86M
Net Margin %	-2.21%	-2.85%	-3.05%	-3.55%	-1.35%	-9.5%	-	-	-	-
Net Income Growth %	-	-1.75%	-0.41%	-0.35%	0.12%	-1.47%	0.03%	-0.94%	-0.37%	-0.33%
Net Income (Continuing)	-6.59M	-18.12M	-25.49M	-34.53M	-31.83M	-74.81M	-72.27M	-140.24M	-192.41M	-255.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.89	-2.45	-3.45	-5.55	-3.97	-6.00	-1.85	-2.26	-2.42	-2.46
EPS Growth %	-	-1.75%	-0.41%	-0.61%	0.28%	-0.51%	0.69%	-0.22%	-0.07%	-0.02%
EPS (Basic)	-1.13	-3.10	-3.45	-5.55	-3.97	-6.00	-1.85	-2.26	-2.42	-2.46
Diluted Shares Outstanding	7.4M	7.4M	7.4M	6.22M	7.62M	11.08M	38.73M	58.74M	79.66M	103.86M
Basic Shares Outstanding	5.86M	5.86M	7.4M	6.22M	7.62M	11.08M	38.73M	58.74M	79.66M	103.86M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	91.1M	69.73M	42.38M	81M	40.59M	244.91M	222.63M	264.97M	270.77M	296.47M
Cash & Short-Term Investments	90.48M	68.51M	40.96M	78.59M	37.42M	242.19M	219.68M	259.28M	265.71M	287.08M
Cash Only	90.48M	41.32M	28.27M	55.67M	37.42M	242.19M	219.68M	139.89M	53.23M	98.17M
Short-Term Investments	0	27.19M	12.69M	22.92M	0	0	0	119.39M	212.48M	188.91M
Accounts Receivable	294K	928K	830K	1.67M	2M	0	0	0	0	0
Days Sales Outstanding	35.94	53.3	36.24	62.55	32.45	-	-	-	-	-
Inventory	0	0	75K	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	326K	0	75K	740K	0	0	0	1.25M	5.06M	9.39M
Total Non-Current Assets+	3.67M	5.82M	6.74M	4.92M	8.83M	6M	9.46M	35.84M	42.67M	31.43M
Property, Plant & Equipment	2.42M	4.56M	4.11M	3.25M	7.15M	4.75M	4.48M	31.1M	30.34M	26.56M
Fixed Asset Turnover	1.24x	1.39x	2.04x	2.99x	3.15x	1.66x	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	1.25M	1.25M	1.25M	1.25M	0	0	0	0	7.46M	0
Other Non-Current Assets	0	0	1.37M	419K	1.68M	1.25M	4.98M	4.75M	4.86M	4.86M
Total Assets+	94.77M	75.55M	49.12M	85.93M	49.42M	250.92M	232.09M	300.81M	313.44M	327.9M
Asset Turnover	0.03x	0.08x	0.17x	0.11x	0.46x	0.03x	-	-	-	-
Asset Growth %	-	-0.2%	-0.35%	0.75%	-0.42%	4.08%	-0.08%	0.3%	0.04%	0.05%
Total Current Liabilities+	7.29M	8.74M	11.19M	24.95M	13.25M	13.09M	17.08M	26.85M	38.17M	55.71M
Accounts Payable	1.4M	1.45M	1.35M	1.52M	3.18M	732K	3.48M	5.84M	10.65M	12.01M
Days Payables Outstanding	-	-	-	-	26.58K	10.38	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	0	1000K	1000K	0	0
Other Current Liabilities	606K	118K	1.64M	3.88M	3.39M	7.28M	3.62M	6.47M	10.31M	12.63M
Current Ratio	12.49x	7.98x	3.79x	3.25x	3.06x	18.70x	13.04x	9.87x	7.09x	5.32x
Quick Ratio	12.49x	7.98x	3.78x	3.25x	3.06x	18.70x	13.04x	9.87x	7.09x	5.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	17.96M	14.43M	9.62M	748K	4.41M	3.15M	831K	18.23M	17.47M	15.9M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	4.41M	3.15M	831K	18.23M	17.47M	15.9M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	665K	908K	906K	748K	0	0	0	0	0	0
Total Liabilities	25.25M	23.16M	20.81M	25.69M	17.66M	16.25M	17.91M	45.08M	55.63M	71.61M
Total Debt+	0	0	0	0	6.03M	5.21M	3.15M	19.65M	18.85M	17.47M
Net Debt	-90.48M	-41.32M	-28.27M	-55.67M	-31.39M	-236.98M	-216.53M	-120.24M	-34.38M	-80.7M
Debt / Equity	-	-	-	-	0.19x	0.02x	0.01x	0.08x	0.07x	0.07x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-37.06x	-	-
Total Equity+	69.52M	52.39M	28.3M	60.23M	31.76M	234.67M	214.18M	255.74M	257.8M	256.29M
Equity Growth %	-	-0.25%	-0.46%	1.13%	-0.47%	6.39%	-0.09%	0.19%	0.01%	-0.01%
Book Value per Share	9.40	7.08	3.83	9.68	4.17	21.18	5.53	4.35	3.24	2.47
Total Shareholders' Equity	69.52M	52.39M	28.3M	60.23M	31.76M	234.67M	214.18M	255.74M	257.8M	256.29M
Common Stock	16K	10K	10K	30K	8K	32K	44K	70K	86K	110K
Retained Earnings	-7.72M	-25.85M	-51.34M	-92.06M	-123.89M	-198.7M	-270.97M	-411.21M	-603.62M	-859.48M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-16K	-24K	-16K	-12K	0	0	0	-104K	246K	447K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	17.72M	-18.64M	-25.84M	-32.49M	-41.51M	-35.85M	-58.76M	-118.64M	-153.62M	-207.79M
Operating CF Margin %	5.93%	-2.93%	-3.09%	-3.34%	-1.85%	-4.55%	-	-	-	-
Operating CF Growth %	-	-2.05%	-0.39%	-0.26%	-0.28%	0.14%	-0.64%	-1.02%	-0.29%	-0.35%
Net Income	-6.59M	-18.12M	-25.49M	-34.53M	-31.83M	-74.81M	-72.27M	-140.24M	-192.41M	-255.86M
Depreciation & Amortization	179K	830K	1.17M	1.32M	1.29M	720K	147K	5.88M	3.59M	4.35M
Stock-Based Compensation	248K	1.02M	1.34M	3.09M	0	6.02M	11.69M	18.37M	30.62M	39.74M
Deferred Taxes	-248K	17K	17K	-236K	0	0	0	0	0	0
Other Non-Cash Items	248K	-56K	7K	23K	3.11M	37.54M	-343K	-3.39M	-6.87M	-7.62M
Working Capital Changes	23.88M	-2.32M	-2.88M	-2.15M	-14.08M	-5.32M	2.02M	751K	11.44M	11.6M
Change in Receivables	-294K	-634K	98K	-838K	-332K	2M	0	0	0	0
Change in Inventory	220K	784K	931K	2.21M	0	0	0	0	0	0
Change in Payables	705K	389K	-31K	367K	1.66M	-2.45M	2.75M	2.36M	4.81M	1.36M
Cash from Investing+	-3.25M	-30.43M	13.51M	-10.53M	23.16M	8.42M	-1.72M	-124.72M	-97.82M	38.28M
Capital Expenditures	-1.99M	-3.31M	-912K	-549K	-33K	0	-1.72M	-6.86M	-2.8M	-573K
CapEx % of Revenue	0.67%	0.52%	0.11%	0.06%	0%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-1.25M	50K	-75K	0	0	8.42M	0	-117.86K	0	0
Cash from Financing+	70.75M	-40K	-729K	70.35M	108K	232.2M	37.98M	163.56M	163.54M	214.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-40K	-789K	-1.45M	0	560K	-30K	1.61M	0	1.11M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	15.72M	-21.95M	-26.75M	-33.04M	-41.55M	-35.85M	-60.48M	-125.5M	-156.42M	-208.36M
FCF Margin %	5.27%	-3.45%	-3.2%	-3.39%	-1.85%	-4.55%	-	-	-	-
FCF Growth %	-	-2.4%	-0.22%	-0.24%	-0.26%	0.14%	-0.69%	-1.08%	-0.25%	-0.33%
FCF per Share	2.13	-2.97	-3.62	-5.31	-5.45	-3.24	-1.56	-2.14	-1.96	-2.01
FCF Conversion (FCF/Net Income)	-2.69x	1.03x	1.01x	0.94x	1.37x	0.48x	0.81x	0.85x	0.80x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-9.48%	-29.73%	-63.18%	-78%	-65.81%	-56.16%	-32.2%	-59.69%	-74.94%	-99.54%
Return on Invested Capital (ROIC)	-	-	-353.34%	-1174.59%	-978.45%	-	-	-166.54%	-86.98%	-103.73%
Gross Margin	100%	100%	100%	100%	99.81%	-227%	-	-	-	-
Net Margin	-220.76%	-285.19%	-304.93%	-354.76%	-134.55%	-950.43%	-	-	-	-
Debt / Equity	-	-	-	-	0.19x	0.02x	0.01x	0.08x	0.07x	0.07x
Interest Coverage	-	-	-	-	-	-	-	-37.06x	-	-
FCF Conversion	-2.69x	1.03x	1.01x	0.94x	1.37x	0.48x	0.81x	0.85x	0.80x	0.81x
Revenue Growth	-	112.83%	31.55%	16.44%	131.14%	-65.02%	-100%	-	-	-

Revenue by Segment

	2018	2019
Preclinical Research And Clinical Development	25M	25M
Preclinical Research And Clinical Development Growth	-	0.00%

Frequently Asked Questions

Growth & Financials

Cogent Biosciences, Inc. (COGT) grew revenue by 0.0% over the past year. Growth has been modest.

Cogent Biosciences, Inc. (COGT) reported a net loss of $294.4M for fiscal year 2024.

Dividend & Returns

Cogent Biosciences, Inc. (COGT) has a return on equity (ROE) of -99.5%. Negative ROE indicates the company is unprofitable.

Cogent Biosciences, Inc. (COGT) had negative free cash flow of $246.7M in fiscal year 2024, likely due to heavy capital investments.